Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome

Author(s): Lucio Tremolizzo, Virginia Rodriguez-Menendez, Elisa Conti, Chiara Paola Zoia, Guido Cavaletti, Carlo Ferrarese

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 11 , 2014

Become EABM
Become Reviewer
Call for Editor


The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation.

Keywords: Neuroepigenome, histone deacetylase, DNA methylation, neuropsychiatric disorders.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 01 April, 2014
Page: [1831 - 1839]
Pages: 9
DOI: 10.2174/13816128113199990535
Price: $65

Article Metrics

PDF: 21